磷酸肌酸二(三羟甲基氨基甲烷)盐 | 108321-17-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 磷酸肌酸二(三羟甲基氨基甲烷)盐
• 英文名称: 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[methyl-[(E)-N'-phosphonocarbamimidoyl]amino]acetic acid
• CAS: 108321-17-1
• 化学式: C8H21N4O8P
• 分子量: 332.25
• InChiKey: GKUKPYOSLHGAGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.93
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  223
• 氢给体数：
  8
• 氢受体数：
  10

安全信息

• WGK Germany：
  3

文献信息

• Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism
  申请人：Smith Sheryl

  公开号：US20070081943A1

  公开（公告）日：2007-04-12

  The present invention is directed to a screening mechanism for identifying members of the general population at increased risk for alcoholism and premenstrual syndrome. The screening mechanisms may be used to measure the expression of the α 4 β 2 δ GABA A receptors, in order to identify members of the general population as having an increased sensitivity to lower concentrations alcohol coupled with a decrease sensitivity to higher concentrations of alcohol, a scenario frequently found in patients suffering from alcoholism and premenstrual anxiety. Methods of screening for drugs which decrease expression of the α 4 β 2 δ subunit of GABA A are also provided.
• Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
  申请人：Smith Sheryl

  公开号：US20090269795A1

  公开（公告）日：2009-10-29

  The present invention provides methods for treating anxiety or irritability in a subject. The methods comprise administering to the subject an effective amount of an antagonist of allopregnanolone (THP), or a regulator which decreases expression of the alpha 4 subunit of GABA such as gabadoxbol (THIP), or a vector comprising an isolated nucleic acid molecule encoding a mutant alpha 4 subunit GABA A receptor protein having a neutral or non-basic amino acid residue substituted for the arginine residue at position 353 of the wild type mature protein, wherein this nucleic acid molecule is operably linked to a promoter which functions in the human brain. Such methods are useful in treating a subject undergoing a stage such as entering or having reached puberty, suffering from pre-menstrual syndrome (PMS), entering or having reached post-partem stage, entering or having reached menopause, and/or suffering from chronic stress. Also provided by the present isolated is a mutant alpha 4 subunit of GABA A receptor protein which has a neutral or non-basic amino acid residue substituted for the arginine residue at position 353 of the wild type mature protein and an isolated nucleic acid molecule encoding this mutated protein. The present invention also provides vectors comprising a subject isolated nucleic acid molecule operably liked to a promoter which functions in prokaryotic or eukaryotic cells, as well as host cells comprising such vectors. In addition, the present invention provides methods for identifying an antagonist of THP.
• In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles
  申请人：Adair James H.

  公开号：US20100247436A1

  公开（公告）日：2010-09-30

  Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.
• IN VIVO PHOTODYNAMIC THERAPY OF CANCER VIA A NEAR INFRARED AGENT ENCAPSULATED IN CALCIUM PHOSPHATE NANOPARTICLES
  申请人：THE PENN STATE RESEARCH FOUNDATION

  公开号：US20140154325A1

  公开（公告）日：2014-06-05

  Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.
• METHOD FOR DELAYED RECTIFIER CURRENT ENHANCEMENT, CHARACTERIZATION, AND ANALYSIS IN HUMAN INDUCED PLURIPOTENT STEM CELLS
  申请人：The Research Foundation for The State University of New York

  公开号：US20200240980A1

  公开（公告）日：2020-07-30

  A method for analyzing a test agent to determine whether or not the test agent affects electrical activity of a cardiomyocyte is disclosed. The method includes: i) providing an induced pluripotent stem cell (iPSC) derived cardiomyocyte (iPSC-DM) that has been modified to contain an oligonucleotide that increases iPSC-DM I Kr ; ii) measuring I Kr and action potential of the iPSC-DM of i); subsequently iii) contacting the iPSC-DM of i) with the test agent; and iv) measuring I Kr and action potential of the iPSC-DM that has been contacted with the test agent; and determining a difference between the I Kr and action potential of ii) and the I Kr and the action potential of iv) to indicate the test agent affects the electrical activity of the cardiomyocyte, or determining the same I Kr and action potential of ii) and iv) to indicate the test agent does not adversely affect the electrical activity of the cardiomyocyte.